News stories about FibroGen (NASDAQ:FGEN) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. FibroGen earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 48.3562026723734 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have effected Accern’s analysis:
- FibroGen (FGEN) Given Hold Rating at Mizuho (americanbankingnews.com)
- New 52 Week High Stock – FibroGen, Inc. (FGEN) (thestocksnews.com)
- FibroGen (FGEN) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
- $28.23 Million in Sales Expected for FibroGen (FGEN) This Quarter (americanbankingnews.com)
- Global Duchenne Muscular Dystrophy Therapeutics Market 2018 – Bristol-Myers Squibb Company, FibroGen … (truthtoday24.com)
Shares of FGEN stock traded up $0.15 during trading hours on Thursday, hitting $46.20. The company had a trading volume of 483,611 shares, compared to its average volume of 615,203. FibroGen has a 12 month low of $22.75 and a 12 month high of $63.00. The firm has a market cap of $3,748.95, a P/E ratio of -26.10 and a beta of 1.76. The company has a current ratio of 9.70, a quick ratio of 9.70 and a debt-to-equity ratio of 0.17.
A number of brokerages recently issued reports on FGEN. ValuEngine cut FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research downgraded FibroGen from a “hold” rating to a “sell” rating in a report on Monday, March 5th. Mizuho set a $61.00 price target on FibroGen and gave the company a “hold” rating in a report on Thursday. BidaskClub downgraded FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Finally, Leerink Swann restated an “outperform” rating and issued a $88.00 target price (up previously from $80.00) on shares of FibroGen in a research note on Wednesday, February 28th. Two analysts have rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $66.67.
In other news, CEO Thomas B. Neff sold 38,636 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $47.61, for a total value of $1,839,459.96. Following the transaction, the chief executive officer now owns 3,029,887 shares of the company’s stock, valued at approximately $144,252,920.07. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider K Peony Yu sold 10,000 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $62.00, for a total value of $620,000.00. Following the completion of the transaction, the insider now directly owns 152,086 shares in the company, valued at approximately $9,429,332. The disclosure for this sale can be found here. Insiders sold a total of 465,435 shares of company stock worth $24,839,079 over the last quarter. Corporate insiders own 13.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “FibroGen (NASDAQ:FGEN) Given Daily Coverage Optimism Score of 0.15” was posted by BBNS and is the property of of BBNS. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://baseballnewssource.com/2018/03/29/fibrogen-fgen-earns-media-sentiment-score-of-0-15/1971065.html.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.